GREATER NOIDA: The Yamuna Expressway industrial development authority (Yeida) is set to come up with a plot scheme in January, 2026 for residential usages for all those who want to have a home near ...
The European Union agreed Wednesday to phase out Russian natural gas imports by late 2027 as part of an effort to end the bloc’s decade-long dependency on Russian energy. Representatives for EU ...
Two North Texas men are facing charges after allegedly plotting to invade an island off Haiti, kill all the men and turn the women and children into their sex slaves, according to the U.S. Attorney's ...
The second season of Return to Paradise is well under way, as episode two saw the dynamic DI Mackenzie Clarke put her skills to good use once more. But we couldn’t help but notice that this new run ...
Many financiers are vowing to play nice with Zohran Mamdani, but some are already thinking about how they will blunt the mayor-elect’s most liberal initiatives. By Lauren Hirsch Wall Street financiers ...
EU considering phase-out of Russian oil and gas by January 2028 Ambassadors agree to forward proposal to ministers - diplomats Ministers' meeting planned for October 20 BRUSSELS, Oct 8 (Reuters) - ...
HONOLULU (KHON2) — The second phase of Skyline has taken two years and three months, and it’s finally ready to open, with many expecting big changes to their commute. Skyline stations transform into ...
Roche dived into the metabolic dysfunction-associated steatohepatitis (MASH) space by agreeing to hand over up to $3.5 billion for 89bio and its phase-3-stage candidate for the fatty liver disease. At ...
Von der Leyen discusses economic pressure on Russia with Trump EU to propose 19th sanctions package targeting crypto, banks, and energy Sept 16 (Reuters) - The European Commission will propose ...
Community driven content discussing all aspects of software development from DevOps to design patterns. The Java ternary operator provides an abbreviated syntax to evaluate a true or false condition, ...
MapLight Therapeutics has raised a $372.5 million series D round, clearing the biotech to chart a course through phase 2 for its would-be challenger to Bristol Myers Squibb’s schizophrenia treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback